Indeed, a recent phase I clinical trial (CARBON) shows how CTX-110, an anti CD19 CAR T-cell in which MHC I complex has been eliminated by CRISPR/Cas9 editing of TCRA and β2M administrated in patient with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) resulted highly efficient (NCT04035434). Here, B2M is linked to diffuse large B-cell lymphoma.